Gapping up
In reaction to strong earnings/guidance: TITN +4.8%, LAYN +3.6%, JPM +2.6%, ADTN +2.4%, FWP +0.5%, CSX +0.4%, .
M&A news: MDVN +8.2% (Bloomberg report discussing potential bid from Sanofi (SNY)), DMD +1.1% (Demand Media agrees to sell Cracked brand to E.W. Scripps for $39 mln in cash),
Select financial related names showing strength (after JPM earnings): DB +6%, SAN +5.4%, CS +5.3%, HSBC +4.9%,BCS +3.9%, ING +2.9%, LYG +2.8%, C +2.3%, BAC +1.9%
Select metals/mining stocks trading higher: MT +6.4%, BBL +5.4%, BHP +5.2%, RIO +4.2%, CLF +3.3%, VALE +2.4%,AKS +1.8%, FCX +1.6%, .
Other news: RPRX +46.9% (reports 'positive' clinical data for vaginal Proellex in women with severe menstrual bleeding due to uterine fibroids ), OCLS +23.7% (receives EU approval to market Sinudox), PTIE +16.2% (FDA determines NDA resubmission for REMOXY is sufficiently complete to permit a substantive review; Sept 25 target action date for PDUFA ), ARWR +13.3% (will present 3 posters including data on ARC-520 at The International Liver Congress), ACUR +12.7% (announces FDA fast track designation for the development of LTX-04 ), APHB +8.3% (presented data at the ECCMID summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01 ),PSTI +7.8% (receives 2 key patents in Japan), CTIC +6% (announced that data highlighting pacritinib, pixantrone and tosedostat will be presented at the upcoming American Association of Cancer Research Annual Meeting), DRRX +4.8% (receives target PDUFA date for REMOXY of Sep 25), FIT +4.6% (still checking, but may be just continued strength from yesterday), MXWL +3.6% (to sell microelectronics product line to Data Device, a subsidiary of ILC Industries, for $21 mln in cash).
Analyst comments: FL +1.9% (upgraded to Overweight from Neutral at Piper Jaffray), THC +1.7% (upgraded to Positive from Neutral at Susquehanna), FSLR +1.3% (initiated with a Buy at Guggenheim)
In reaction to strong earnings/guidance: TITN +4.8%, LAYN +3.6%, JPM +2.6%, ADTN +2.4%, FWP +0.5%, CSX +0.4%, .
M&A news: MDVN +8.2% (Bloomberg report discussing potential bid from Sanofi (SNY)), DMD +1.1% (Demand Media agrees to sell Cracked brand to E.W. Scripps for $39 mln in cash),
Select financial related names showing strength (after JPM earnings): DB +6%, SAN +5.4%, CS +5.3%, HSBC +4.9%,BCS +3.9%, ING +2.9%, LYG +2.8%, C +2.3%, BAC +1.9%
Select metals/mining stocks trading higher: MT +6.4%, BBL +5.4%, BHP +5.2%, RIO +4.2%, CLF +3.3%, VALE +2.4%,AKS +1.8%, FCX +1.6%, .
Other news: RPRX +46.9% (reports 'positive' clinical data for vaginal Proellex in women with severe menstrual bleeding due to uterine fibroids ), OCLS +23.7% (receives EU approval to market Sinudox), PTIE +16.2% (FDA determines NDA resubmission for REMOXY is sufficiently complete to permit a substantive review; Sept 25 target action date for PDUFA ), ARWR +13.3% (will present 3 posters including data on ARC-520 at The International Liver Congress), ACUR +12.7% (announces FDA fast track designation for the development of LTX-04 ), APHB +8.3% (presented data at the ECCMID summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01 ),PSTI +7.8% (receives 2 key patents in Japan), CTIC +6% (announced that data highlighting pacritinib, pixantrone and tosedostat will be presented at the upcoming American Association of Cancer Research Annual Meeting), DRRX +4.8% (receives target PDUFA date for REMOXY of Sep 25), FIT +4.6% (still checking, but may be just continued strength from yesterday), MXWL +3.6% (to sell microelectronics product line to Data Device, a subsidiary of ILC Industries, for $21 mln in cash).
Analyst comments: FL +1.9% (upgraded to Overweight from Neutral at Piper Jaffray), THC +1.7% (upgraded to Positive from Neutral at Susquehanna), FSLR +1.3% (initiated with a Buy at Guggenheim)